Skip to content

Advertisement

Journal of Translational Medicine

Research
Open Access

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients

  • Maria Libera Ascierto1, 8, 13Email author,
  • Michael O Idowu2,
  • Yingdong Zhao3,
  • Hanif Khalak4,
  • Kyle K Payne5,
  • Xiang-Yang Wang6,
  • Catherine I Dumur2,
  • Davide Bedognetti1,
  • Sara Tomei4,
  • Paolo A Ascierto7,
  • Anil Shanker11,
  • Harry D Bear9,
  • Ena Wang1,
  • Francesco M Marincola1, 12,
  • Andrea De Maria8, 10 and
  • Masoud H Manjili5
Journal of Translational Medicine201311:145

https://doi.org/10.1186/1479-5876-11-145

©  Ascierto et al.; licensee BioMed Central Ltd. 2013

Received: 1 March 2013

Accepted: 4 June 2013

Published: 12 June 2013

Abstract

Background

Recent observations suggest that immune-mediated tissue destruction is dependent upon coordinate activation of immune genes expressed by cells of the innate and adaptive immune systems.

Methods

Here, we performed a retrospective pilot study to investigate whether the coordinate expression of molecular signature mostly associated with NK cells could be used to segregate breast cancer patients into relapse and relapse-free outcomes.

Results

By analyzing primary breast cancer specimens derived from patients who experienced either 58–116 months (~5-9 years) relapse-free survival or developed tumor relapse within 9–76 months (~1-6 years) we found that the expression of molecules involved in activating signaling of NK cells and in NK cells: target interaction is increased in patients with favorable prognosis.

Conclusions

The parameters identified in this study, together with the prognostic signature previously reported by our group, highlight the cooperation between the innate and adaptive immune components within the tumor microenvironment.

Keywords

Breast cancer prognosisMolecular markersInnate immunityNK cellsTumour relapseTumour microenvironment

Background

Increasing evidence indicates that some patients with cancer can generate an adaptive immune response specifically directed against antigenic proteins expressed by tumors. In particular, an adaptive T cell response, which is composed of both cytotoxic CD8+ T cells (CTLs) and CD4+ T cells, can promote the secretion of cytokines such as interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα) generating an acute inflammation which results in expansion of cytotoxic CD8+ T cells, tissue destruction and control of cancer growth [1]. Accordingly, an “adaptive immune response” signature has been associated with improved outcomes in several tumour types [1–4]. Thus, in the context of tumor immune surveillance most emphasis has been placed on adaptive immune responses while the role of innate immune cells and their cross talk with adaptive immune cells as played a minor role. However, recent observations suggest that immune-mediated tissue destruction, which includes tumour regression, is dependent upon coordinate activation of immune effector genes expressed by cells of the innate and adaptive immune systems [1, 5–8]. Recently, we have shown that the anti-tumour efficacy of Adoptive Cell Therapy (ACT) in the FVBN202 transgenic mouse model of breast carcinoma depended on the presence of tumour-specific T cells as well as activated Natural Killer (NK) cells and NKT cells [9]. Among cells of the innate immune system, the NK cells represent a subset of lymphocytes that can rapidly respond to the presence of tumour cells and participate in antitumor responses [10]. The effective function of NK cells is strictly dependent on the balance in the expression of activating and inhibitory receptors which are able to interact with ligands present on the target cells [11]. NK cells also express adhesion molecules able to interact with tumour cells or dendritic cells (DCs), resulting in NK cell cytotoxicity or enhanced DC activation, respectively. The anti-tumour effect of NK cells has been well documented especially in animal models showing that reduced NK cell activity leads to a high incidence of tumour occurrence and metastasis [12, 13]. Tumour rejection in mice has been correlated with precursor frequency of both tumour-specific CD8+ T cells and NK effector cells that interact with tumour cells via activating receptor Natural Killer Group 2D (NKG2D)-mediated mechanisms [14]. In humans, while prognostic T cell signatures are widely established, the role of NK cells or other immune effector cells has been poorly appreciated. Only recently it has been observed that a decrease in the expression of the activating receptors NKG2D and DNAX accessory molecule 1(DNAM1) by NK cells is associated with tumour progression in breast cancer patients [15]. Similar observations were made in the tumour types such as chronic lymphocytic leukaemia (CLL) and gastrointestinal stromal tumours (GIST) [16, 17], showing that an increased expression of Natural Cytotoxicity Receptors (NCRs) was associated with survival of patients. Recently, we reported that an increased expression of the immune function genes was associated with relapse-free survival in patients with breast cancer [18]. Using the same cohort of patients, we sought to determine prognostic value of the innate immune response characterized by a differential expression of molecular signatures mostly associated with activating signalling of NK cells and their crosstalk with target cells. Here, we showed that the expression of Natural Cytoxicity Receptor 1 (NCR1), considered the most accurate surface markers for human NK cell identification [19, 20], together with molecules mostly associated with NK cells and involved in NK cells: target cells interactions, are associated with prolonged relapse-free survival in breast cancer patients. On the contrary, we found that differential expression of CD56 and CD16 in tumour specimens as well as the expression of Killer-cell Immunoglobulin-like Receptors (KIRs) transcripts failed to do so.

Material and methods

Clinical specimens

Patients experiencing either 58–116 months (~5-9 years) relapse-free survival or tumour relapse within 9–76 months (~1-6 years) following initial surgery were studied. Samples were collected from female breast cancer patients’ definitive surgery specimens. Specimens with unknown tumour stage, lost to follow-up or HER-2/neu borderline were not included in our analyses. Frozen tissues derived from 14 patients (7 who were relapse-free and 7 whose tumours relapsed) were used for microarray analysis. Among the samples screened by microarray, only 11 samples were also screened for RT-PCR because of lack of additional total RNA to analyse. Additionally 5 new samples were included in the RT-PCR analysis reaching a total group of 16 analyzed samples. Paraffin-embedded tissues derived from 9 patients including 4 relapse patients and 5 relapse-free patients were also used for immunohistochemistry (IHC). Patients used in each assay and detailed patients’ information are further described in Additional file 1: Table S1.

All the patients have signed an Informed Consent Form and approved the publication of this report and any accompanying images. The study was reviewed and approved by the Institutional Review Board (HM10920 and 2471-Tissue Acquisition System for Cancer Research) at Virginia Commonwealth University.

RNA amplification, probe preparation, microarray hybridization

Gene profiling analysis was performed on a 36 k human oligo array as previous described [21].

Whole-genome human 36 K oligo arrays, representing 25100 unique genes of the Operon Human Genome Array–Ready OligoSet version 4.0 were printed in house using oligos purchased from Operon. The designed is based on Ensemble Huma Databasebuil NCBI-35c, with a full coverage on the NCBI human Refseq dataset (04/04/2005).

Reference for human arrays was obtained by pooling PBMCs from 6 normal donors.

Total RNA from tumour and reference samples were isolated and amplified into antisense RNA (aRNA) as previously described [22, 23]. Both reference and test aRNA were directly labelled using ULS aRNA Fluorescent Labelling kit (Kreatech Diagnostics, Amsterdam, The Netherlands) with Hy3 and Hy5 respectively and co-hybridized to the slides. After 20 hours of incubation at 42°C, the arrays were washed, dried and scanned using the Agilent Microarray Scanner.

Real-Time (RT)-PCR

Real Time-PCR was assayed by TaqMan® Gene Expression Assays (Applied Biosystems, Foster City, CA) using an ABI PRISM 7900HT Sequence Detection System. Primers and probes were obtained from ABI (TaqMan Assays-on-Demand gene expression products, Applied Biosystems). To normalize the amount of source RNA, 18S transcript from the same sample was measured and used as internal reference. Each targeted transcript was validated using the comparative Ct method for relative quantification (ΔΔCt) reference to the amount of a common reference gene (18S) using PBMCs from healthy donors. The fold difference between relapse-free and progressing groups was calculated using the comparative 2–ΔΔCt [24].

Statistical analysis

Microarray data were uploaded to the mAdb databank (http://nciarray.nci.nih.gov) and further analysed using Partek (St. Louis, Missouri, USA) and BRBArrayTools developed by the Biometric Research Branch, NCI (http://linus.nci.nih.gov/BRB-ArrayTools.html) [25]. The whole gene expression profile consisted of 25100 genes. Unsupervised analysis was performed for class confirmation using Stanford Cluster Program and TreeView software [26]. Gene ratios were average corrected across experimental samples and displayed according to uncentered algorithm. Functional gene network analysis was performed using the Ingenuity Pathway Analysis system (IPA).

RT-PCR data were analysed using MedCalc Software (Mariakerke, Belgium), StatGraphics Centurion (Warrenton,Virginia, USA) and BRBArrayTools; to determine the difference of mRNA expression among relapse and relapse-free groups Mann-Witney test using MedCalc Software and StatGraphics Centurion were considered. Survival analysis, survival risk prediction analysis and Support Vector Machine (SVM) were performed using BRBArrayTools [25]. Univariant Cox proportional hazards models were fit to test individual NK selected gene expression levels for association with survival (Wald test, two-sided). Kaplan-Meier survival curves were plotted for patients with expression levels above and below the median for each NK selected gene. Permutation p-values for significant genes were computed based on 10000 random permutations. Hazard ratio is considered as the ratio of hazards for a two-fold change in the gene expression level. It is equal to exp(b) where b is the Cox regression coefficient.

A survival risk prediction model was built using the supervised principal component method of Bair and Tibshirani [27]. A Cox proportional hazards model was fit to relate relapse time to the first two principal component linear combinations of expression levels from 8 significantly expressed genes screened by RT-PCR. In order to evaluate the predictive value of the method, leave-one-out cross-validation was used. A high relapse index value corresponded to a high predicted hazard of relapse with correspondingly poor predicted outcome. The cross validated Kaplan-Meier survival curves were plotted for cases predicted to have above average risk (relapse index above the median in the cross-validated model) and for cases predicted to have below average risk (relapse index below the median in the cross-validated model). A permutation analysis was performed in which the relapse data was randomly shuffled among cases 1000 times and the entire cross-validation process was repeated in order to assess whether the association of expression data to relapse data was statistically significant. The log-rank statistics was generated for those permutations.

Support vector machine (SVM) with linear kernel functions was used to develop the prediction model for distinguishing relapse-free patients and progressing patients.

In order to estimate how accurately the classes can be predicted by this multivariate class predictor, the leave-one-out cross-validated (LOOCV) misclassification rate as well as cross- validation ROC curve analysis were computed. Permutation p value for the cross-validated misclassification error rate was also calculated by randomly shuffling the class labels 1000 times and repeating the entire cross validation procedure.

Gene expression-based Outcome for Breast cancer Online (GOBO) tool (http://co.bmc.lu.se/gobo) [28], was used to perform in silico analyses and develop Kaplan-Meier analysis on for breast cancer patients (n = 115) derived from four publicly available breast cancer datasets of gene expression [29-32]. The results were stratified into the two quintiles based on gene expression level of NCR3(NKp30), NCR1(NKp46), CD96, CRTAM, DNAM1 and NKG2D.

Immunohistochemistry (IHC)

Slides from paraffin-embedded tumour specimens were subjected to Dako automated immunostainer (Dako, Carpinteria, CA). Anti-human antibodies towards NCR1 (NKp46) (Abcam Ab14823, 1:100), LFA-1 (Abcam ab52895, 1:250) and CD1d (Abcam, Ab11076, 1:100) were used. The antigen retrieval was achieved using DAKO PT module at high PH. In order to circumvent the endogenous biotin activity, we used Dako Envision Dual Link System-HRP (Dako, Capinteria CA) in a two-step IHC technique, based on HRP labelled polymer which is conjugated with secondary antibodies. The labelled polymer does not contain avidin or biotin, thereby avoiding the nonspecific endogenous avidin-biotin activity in the sections.

Results

Differential expression of genes involved in NK signature in breast cancer patients with favourable prognosis

Microarray analyses were performed on amplified RNA extracted from frozen tissues derived from 14 patients with either relapse free survival or tumour relapse (Additional file 1: Table S1). Unsupervised clustering performed on the filtered gene set (see material and methods) and based on DNAM1, NCR3(NKp30), CD96 and Class I–Restricted T-cell–Associated Molecule (CRTAM) expression signatures was able to spontaneously segregate the breast cancer patients in two distinct cohorts (Figure 1A). Unpaired Student’s t-test (p ≤ 0.001) was used to identify genes differentially expressed in relapse-free and relapsed groups. The cohort of the identified genes was further analyzed by IPA showing that genes involved in NK-DCs crosstalk (Additional file 2: Figure S1) and NK cells signalling (Additional file 3: Figure S2) were over-expressed in patients with favourable prognosis.
Figure 1
Figure 1

Expression of genes involved in prognostic NK signature. A) Unsupervised clustering based on genes involved in NK cell activation and interaction with tumour cells. B) Similarity matrix based on Pearson correlation assayed on a total of 15 including genes associated with NK, NKT and genes previously identified to predict breast cancer patients’ clinical outcome genes [6]. Genes previously identified are indicated with *. C) Principal Component Analysis based on 15 genes evaluated in 1B comparing relapse-free (red colour) and progressing (blue colour) patients.

Expression of genes involved in NK signature correlates with previously identified immune function gene signatures associated with favourable outcome

To test whether the expression of molecules mostly associated with NK cell signature correlated with the expression of 5 gene prognostic signature (STAT1, GBP1, OCLN, IGKC and IGL@) previously described by our group [6], a similarity matrix based on Pearson correlation was assembled considering 15 genes (KIR3DL3, KIR2DL3, KIR3DL2, KIR2DL4, CD84, NCR3(NKp30), CD96, CRTAM, DNAM1, CD1d, IGK@, GBP1, STAT1, IGLL5, and OCLN). We observed that the expression of genes involved in NK crosstalk with DCs and tumour cells (DNAM1, CRTAM, CD96), promoting NK cell activation (NCR3(NKp30)) or modulating NKT activity (CD1d) was strongly and positively correlated with that of the 5 previously identified markers of good prognosis. Conversely, genes known to encode for surface proteins that mediate MHC class-I mediated inhibition of NK cells, such as the KIRs receptors showed a negative correlation with the identified 5 immune gene signature (Figure 1B). Interestingly, there was an inverse correlation between the expression of the activating NK receptors, DNAM1 and NCR3, and CD84, a member of the signaling lymphocyte activation molecule (SLAM) immunoglobulin super family. Interaction of CD84 with SH2D1 provides activating stimuli for NK cells and T cells. On the other hand, the expression of CD84 has been reported to be critical for the survival of Chronic Lymphocytic Leukemia (CLL) [33] cells, suggesting an involvement in malignancy. Such controversial reports suggest that the biologic function of CD84 still remains to be determined.

Principal Component Analysis (PCA) based on the 15 genes set demonstrated that relapse-free patients (red colour) segregated apart from those with tumour relapse (Figure 1C), suggesting that the selected signature could be used to clearly differentiate the two cohort of patients. This confirmed previous observations suggesting that the balance between inhibitory and activating pathways in NK cells are finely regulated at the transcriptional level and activating pathways are important modulators of NK function in the tumour microenvironment.

Increased expression of NK activating genes and NK adhesion molecules in patients without recurrence

Results obtained from microarray analysis were further validated by conducting RT-PCR analysis. Because of the lack of additional total RNA, only 11 out of 14 samples previously screened by microarray analysis, were used for the RT-PCR screening. In addition to 11 samples, 5 independent samples, not previously screened by microarray analysis, were included in the analysis. Total RNA derived from the specimens of the16 patients were evaluated for the expression of 4 adhesion molecules which although not only expressed by NK cells are mostly involved in NK-target cells interaction (CRTAM, CD96, CD1d and Leukocyte Function-associated Antigen 1-LFA-1). Also genes involved in NK cell identification and activation were investigated (CD56, CD16, NKG2D, DNAM1). As already mentioned the above molecules are mostly associated with NK cells identification, activation and function, but they can be also shared with a fraction of other immune cells (e.g. T cells, NKT). Therefore 3 additional genes (NCR1(NKp46), NCR2(NKp44), NCR3(NKp30)) mostly restricted to NK cells [19] were screened. Intrigued by the fact that the expression of the 3 different isoforms of NCR3(NKp30) was differently associated with prolonged survival of patients with gastric GISTs [16], we performed quantitative RT-PCR using NCR3(NKp30) primers specific for the three isoforms, in order to investigate whether the expression of different isoforms of NCR3(NKp30) was differentially associated with the clinical outcomes also of individuals with breast cancer. Furthermore, we studied the expression of Forkhead box P3 (FOXP3), usually associated with the presence of T regulatory cells (Tregs) known to inhibit the activity of NK cells and to promote immune suppression function [34]. Based on differential expression of CD56 and CD16, NK cells did not vary between relapse free and progressing groups (p value = 0.3 and 0.8, respectively) (Figure 2A). However, tumours from patients with no recurrence were characterized by increased expression of genes involved in the interaction between NK cells and dendritic cells or tumour cells such as CD1d, CRTAM and CD96 (Figure 2B) and genes involved in activating signalling of NK cells such as NCR1(NKp46), DNAM1 and NKG2D (Figure 2C). Although all the three isoforms of the activating receptor NCR3(NKp30) are showed to be over expressed in the relapse-free group, only isoform1 was found to be significantly different (Figure 2D). Although not statistically significant, the activating receptor NCR2(NKp44) and the adhesive molecule LFA-1 were increased in the relapse free group (Figure 2B-2C).
Figure 2
Figure 2

RT-PCR analysis of relapse free and progressing patients. A) Expression of NK identification markers ; B) Expression of genes encoding for molecules involved in NK crosstalk with target cells; C) Expression of genes involved in activation of NK functions; D) Expression of different isoforms of NCR3 (NKp30).

Interestingly, RT-PCR results also highlighted a positive correlation between the expression of FOXP3 and favourable prognostic NK cells signature (Additional file 4: Figure S3A). One of the limitations of the current analysis is that the RT-PCR screening was mostly conducted on specimens already screened by microarray analysis and only 5 independent specimens were used. Thus, we cannot conclude that the differences observed are not biased by the individual genetic characteristics of the tumours; in order to widely validate the obtained results additional breast specimen’s collection is currently ongoing.

Lack of prediction of breast cancer patients based on KIRs expression

Together with the 12 genes mentioned above, all 16 patients were also screened by RT-PCR for the expression of KIR2DL3, KIR3DL3 and KIR2DL2. The obtained data showed that expression of KIRs was not significantly different in groups with differential survival outcome (Additional file 4: Figure S3B) suggesting that genes involved in activating rather than inhibitory function of NK cells should be considered a potential predictive signature for better survival in breast cancer patients.

Increased percentage of CD1d + and LFA + tumour cells in patients without recurrence

Protein validation analysis was performed by IHC using a set of 9 validation samples (Additional file 1: Table S1). Low levels of protein expression didn’t allow a clear detection of the NK specific marker NCR1 (NKp46) in both relapse-free and progressing patients (data not shown). Instead, tumour specimens of patients with relapse-free survival showed a higher percentage of CD1d + cells. Moreover a higher percentage of LFA-1+ cells was observed in patients with better outcome (Additional file 4: Figure S3C). The presence of CD1d and LFA on NKT cells and a small population of CD8+ cells, together with the lack of detection of Nkp46 signalling, didn't highlight a specific involvement of NK cells in favourable prognosis, at protein level. Although we consider this as a limit of our study, since we are looking for molecular signatures that may be associated with the potential triggering rather than with identification of individual cells involved with favourable outcome, the absence of additional IHC information can be considered a minor obstacle. In addition, if we consider that the screening of NK cells by IHC has always been centre of debate for lack of specificity and/or lack of protein detection, a molecular screening might seem more appropriate.

NK cell signature predict patients outcome based on support vector machine prediction model

To test whether the genes screened by RT-PCR could be used to predict breast cancer patients’ outcome, SVM was used to develop the prediction model for distinguishing relapse-free patients and progressing patients. Among all the genes screened by RT-PCR, only 8 genes (DNAM1, CD96, CD1d, NKG2D, FOXP3 and NCR1(NKP46), NCR3(NKP30) isoform1 and CRTAM) with significantly difference p ≤ 0.05 between the two cohorts of patients were used in the following analysis.

LOOCV analysis showed that the combination of the selected genes was able to predict with an accuracy of 81% patients’ outcome with 90% sensitivity and 66% specificity (Table 1). Based on 1000 permutations, the support vector machines classifier had p-value of 0.004 confirming that among the screened markers, the genes involved in NK cells function are significant predictors of breast cancer outcome. The same results were confirmed by Cross- Validation ROC curve analysis resulting in Area Under the Curve (AUC) equal to 0.91 (Figure 3A).
Table 1

Performance of the support vector machine classifier

Class

Sensitivity

Specificity

PPV

NPV

0

0.9

0.667

0.818

0.8

1

0.667

0.9

0.8

0.818

Support vector machine predictor was built as a linear function of the log-ratios of the expressions of 8 genes screened by RT-PCR. According to our LOOCV results, the 8 selected genes were able to predict with an accuracy of 81% patients’ outcome with 90% sensitivity and 66% specificity.

Figure 3
Figure 3

Prediction models associated with survival and clinical outcome of breast cancer patients. A) Cross-validation ROC curve analysis based on 8 genes (NCR1(NKP46), NCR3(NKp30) isoform1, NKG2D, CRTAM, DNAM1, CD96, CD1d) significantly and differentially expressed in relapse free and progressing patients based on RT-PCR analysis; B) Survival analysis based on the same group of genes. In the figure are reported only Kaplan Mayer curves of 4 genes with significant p value; C) Survival risk prediction analysis based on the same group of genes. D) Kaplan-Meier analysis, using RFS as endpoint, for breast tumors (n = 115) stratified into the two quintiles based on gene expression level of NCR1(NKP46), NCR3(NKp30), NKG2D, DNAM1 and CD96.

Survival analysis and survival risk prediction model based on NK cell signature

In order to evaluate whether the molecular expression of genes differentially expressed among progressing vs. relapse-free groups could predict the survival of breast cancer patients, we performed by BRB array tools a survival analysis based on Cox proportional hazard models. Among the 12 genes screened by RT-PCR, only the 8 genes with significant differences among the two cohorts of patients were used in the following analysis.

Survival was related to each gene testing the hypothesis that survival time is independent of the expression level for that gene. A gene list was created based on the resulting p values which were challenged by a multivariate permutation test to control for the number or proportion of false discoveries. The results showed that the expression of CD96, NKG2D, CD96 and NCR1(NKp46) were significantly associated with survival of breast cancer patients (Figure 3B-Additional file 5: Table S2). Furthermore, survival risk prediction analysis demonstrated that the combined expressions of the selected genes was associated with decreased risk of disease progression, although the limited number of patients used in the analysis didn’t allow the permutation p-value of the log-rank test statistics between risk groups to be significant (p = 0.1, Figure 3C). In order to test whether the described result was associated with the age of patients or with their status of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) status rather than being related to the expression of NK cell signature described above, we performed a survival risk analysis using age, ER, PR and HER2 status as covariants. The results didn’t show an association between decreased risk of disease progression linked with the ER, PR and HER2 expression nor with age (Additional file 4: Figure S3D). In order to determine whether small number of samples may affect our results, by using GOBO tool [28] we conducted survival analysis on a larger cohort of breast cancer patients (n = 115) derived from four publicly available breast cancer datasets of gene expression [29–32]. Kaplan Meyer curves showed a significantly (p < 0.03) better survival for patients that showed higher expression of the NCR3 (NKp30), NCR1(NKp46), CD96, CRTAM, DNAM1 and NKG2D (Figure 3D).

Discussion

The relevance of anti-tumour immune responses as modulators of cancer growth is increasingly recognized and most emphasis has been placed on adaptive immune responses. Yet, cross talk between the innate and adaptive immune systems may be a prerequisite for tumour rejection as recently described [1, 8, 35–37]. NK cells are proposed to be one of the major cells of the innate immune system involved in anti-tumour protection [37]. In human, it has been shown that the presence of intratumoral NK cells is positively correlated with favorable prognosis in colorectal, renal, lung cancer and hepatocellular carcinoma [38–41]suggesting that NK cells may represent a potential prognostic marker [42]. However, in the majority of these studies NK cells have been detected according to the expression of CD57 or CD56 markers which inaccurately identify NK cells since they are also expressed by other tumor-infiltrating lymphoid cells. Thus the involvement of NK cells in tumor immune surveillance has always been in the centre of debate.

Recently the advent of high throughput technology, mostly based on gene expression profiling has shown the relevance of the prognostic infiltration of NK cell markers at the tumor site.

A recent meta analysis conducted on a large publicly available set of microarray data from primary breast tumours suggested that breast cancer displayed variable expression of ligands for NK cell receptors. In particular, NKG2D-ligands and DNAM1-ligands, known for their NK cell activating function, were found to be widely expressed across all breast cancer subtypes [43]. The same group reported that expression of activating NK cell receptors decreased while expression of NK cell inhibitory receptors increased during breast cancer progression [15]. However, a comparative analysis of the expression of these markers in primary tumours directly linked to relapse-free survival has not been performed.

In the present study, we used gene expression profiling, RT-PCR and IHC analysis to detect the expression of activating and adhesive NK cell receptors in primary breast cancer specimens derived from patients who experienced either 58–116 months (~5-9 years) relapse-free survival or developed tumour relapse within 9–76 months (~1-6 years) following surgical resection.

Our results showed that the expression of the genes CD96, CD1d, CRTAM, LFA-1 and DNAM1, involved in the interaction of NK cells with target cells such as tumour cells or DCs, increased in patients with favourable prognosis. NK cells and DCs can exchange bidirectional activating signals in a positive feedback loop. DCs can support innate immunity by promoting the production of cytokines and cytotoxicity of NK cells against cancer. Reciprocally, NK cells have been shown to play immunoregulatory ‘helper’ functions, being able to activate DCs and to enhance their ability to produce pro-inflammatory cytokines during T cell responses [44]. The receptors CD96, CRTAM and DNAM1 promote adhesion of NK cells to target cells expressing the Poliovirus Receptor (PVR or CD155) [45, 46]. This will in turn stimulate cytotoxic function of the NK cells and CD8+ T-cell secretion of IFN-γ in vitro as well as NK cell–mediated rejection of tumours in vivo. Also LFA-1 is critical for NK cell cytotoxicity as it mediates NK-cell binding to intercellular adhesion molecule1 (ICAM1) on target cells, generating activating signals that lead to polarization of the actin cytoskeleton and cytotoxic granules followed by perforin and granzymes exocytosis [47]. Besides its role in the crosstalk with target cells, DNAM1 together with the NKG2D, is considered one of the most important activating receptors expressed on NK cells. However, the molecules CD96, CRTAM and LFA1 may be expressed by activated CD8+ and CD4+ T cells as well as monocytes [19, 48]. DNAM1 or NKG2D may also be expressed by T cells. However, it should be noticed the expression of these molecules was positively and significantly associated (R value > 0.86) with the transcription of activating receptors NCRs, considered mostly restricted to NK cells [19, 49, 50] . In addition, the expression of NCR1 (NKp46), considered the most accurate marker used for NK cell identification, was observed to be significantly increased in patients with favorable outcome ( p value 0.02) and was significantly associated with better survival of the patients (p value 0.03).

Although the number of patients screened for the breast cancer transcriptomic study was small, survival analyses performed on a larger number of breast cancer patients (n = 115) derived from four publicly available breast cancer datasets of gene expression [29–32] revealed a significantly (p < 0.03) better survival for patients that showed higher expression of the NCR3 (NKp30), NCR1 (NKp46), CD96, CRTAM, DNAM1 and NKG2D. This suggests that, together with cells of adaptive immune system, NK cells might play an important role in the context of tumor immune surveillance. The absence of detection of NCR1 (NKp46) by IHC didn’t allow us to validate at protein level a differential expression of NKp46 in patients with widely diverging outcomes. Although we consider this as a limit of the present study, it is important to noticed that the evaluation of NCR1 (NKp46) expression by IHC, as well as the evaluation of the NCR2 (Nkp44) and NCR3 (NKp30), has always been centre of debate for lack of an appropriate detection.

Thus a molecular screening is preferred and might be more accurate and useful in clinical practice.

Our results also showed that the expression of KIRs transcripts including KIR2DL3, KIR3DL3 and KIR2DL2 was negatively and significantly correlated with NCRs expression (R value < -0.7) and was not significantly different in patients with widely diverging outcomes. This evidence suggests that the balance between inhibitory and activating pathways in NK cells is finely regulated at the transcriptional level. Thus, molecules involved in activating signaling of NK cells, rather than in inhibitory one, might be considered central modulators of NK cells function in the tumor microenvironment.

Furthermore, the expression of NK activating genes was positive and significantly correlate with the expression of molecules involved in Th1 signaling, which we already reported to be associated with patients’ favorable outcome [6]. This suggests that, in the tumor microenvironment, the evaluation of collaboration between the innate and adaptive immune systems may be more relevant than single system/cell analysis.

A paradoxical positive association was found between favorable outcome and expression of FOXP3, previously reported to be associated with worse overall survival of patients with breast cancer [51]. This observation is, however, in line with other studies on patients with colon cancer where an association between the infiltration of FOXP3+ T cells and favorable prognosis was evident [52–54]. In addition, emerging evidence suggest that FOXP3 is variably expressed in T cells during activation [55], as well as on tumor cells [56, 57]. Finally, activated NK cells may dominate and overcome tumor-induced immune suppression as previously reported by our group [15].

Conclusions

Results from the present study, together with our recently published work [6], underline the pivotal role played by the innate and adaptive immune systems in the tumour milieu and their coordinated action against cancer progression. Thus, the evaluation of collaboration between the innate and adaptive immune systems may be more relevant than single system/cell analysis. In order to evaluate whether the described results are specific for breast cancer or can be more broadly associated with different cancer types, similar analysis are now ongoing on specimens derived from patients with different tumour types.

The identification of a subtle variation between different tumours in the regulation of molecules mostly associated to NK cells may lead to a better understanding of the intimate relationship between different types of cancer and the immune system.

Notes

Declarations

Acknowledgment

We gratefully acknowledge the support of VCU Massey Cancer Centre, the Commonwealth Foundation for Cancer Research.

Funding

Patient tissue samples and services in support of the research project were provided by the VCU Massey Cancer Centre Tissue and Data Acquisition and Analysis Core, supported, in part, with funding from NIH-NCI Cancer Centre Support Grant P30 CA016059. Davide Bedognetti was supported by the Conquer Cancer Foundation of the American Society of Clinical Oncology (2011 YIA). MH Manjili, HD Bear, MO Idowu, CI Dumur, KK Payne, E Wang and FM Marincola hold a patent assigned to Virginia Commonwealth University (VCU) titled “Gene Signatures with rejection or recurrence of Cancer” PCT/US2012/030312.

Authors’ Affiliations

(1)
Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and FOCIS Center of Excellence, National Institutes of Health, Bethesda, USA
(2)
Department of Pathology, Virginia Commonwealth University, Massey Cancer Centre, Richmond, USA
(3)
Biometric research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, USA
(4)
Weill Cornell Medical College (WCMC), Doha, Qatar
(5)
Department of Microbiology & Immunology, Virginia Commonwealth University, Massey Cancer Centre, Richmond, USA
(6)
Department of Human Genetics, Virginia Commonwealth University, Massey Cancer Centre, Richmond, USA
(7)
Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori Fondazione “G. Pascale”, Naples, Italy
(8)
Department of Health Sciences and Centre of Excellence for Biomedical Research University of Genoa, Genoa, Italy
(9)
Department of Surgery, Virginia Commonwealth University, Massey Cancer Centre, Richmond, USA
(10)
IRCCS Az.Osp.Univ., San Martino-IST Istituto Nazionale Ricerca sul Cancro, Genoa, Italy
(11)
Laboratory of Lymphocyte Function, Department of Biochemistry & Cancer Biology, School of Medicine, Meharry Medical College, Vanderbilt-Ingram Cancer Centre, Vanderbilt University, Nashville, USA
(12)
Chief Research Officer Sidra Medical and Research Centre, Doha, Qatar
(13)
Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, National Institutes of Health, Bethesda, USA

References

  1. Ascierto ML, Giorgi VD, Liu Q, Bedognetti D, Spivey TL, Murtas D, Uccellini L, Ayotte BD, Stroncek DF, Chouchane L: An immunologic portrait of cancer. J Transl Med. 2011, 9: 146-10.1186/1479-5876-9-146.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964. 10.1126/science.1129139.View ArticlePubMedGoogle Scholar
  3. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P: In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009, 27: 5944-5951. 10.1200/JCO.2008.19.6147.View ArticlePubMedGoogle Scholar
  4. Schumacher K, Haensch W, Roefzaad C, Schlag PM: Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001, 61: 3932-3936.PubMedGoogle Scholar
  5. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM, Marincola FM, Garrido F, Cabrera T: Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer. 2012, 131: 387-395. 10.1002/ijc.26471.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY: A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2012, 131: 871-880. 10.1007/s10549-011-1470-x.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Shanker A, Verdeil G, Buferne M, Inderberg-Suso EM, Puthier D, Joly F, Nguyen C, Leserman L, Auphan-Anezin N, Schmitt-Verhulst AM: CD8 T cell help for innate antitumor immunity. J Immunol. 2007, 179: 6651-6662.View ArticlePubMedGoogle Scholar
  8. Wang E, Worschech A, Marincola FM: The immunologic constant of rejection. Trends Immunol. 2008, 29: 256-262. 10.1016/j.it.2008.03.002.View ArticlePubMedGoogle Scholar
  9. Kmieciak M, Basu D, Payne KK, Toor A, Yacoub A, Wang XY, Smith L, Bear HD, Manjili MH: Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol. 2011, 187: 708-717. 10.4049/jimmunol.1100502.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Moretta L: NK cell-mediated immune response against cancer. Surg Oncol. 2007, 16 (Suppl 1): S3-5.View ArticlePubMedGoogle Scholar
  11. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L: Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012, 12: 239-252. 10.1038/nri3174.View ArticlePubMedGoogle Scholar
  12. Ames IH, Garcia AM, John PA, Litty CA, Farrell MA, Tomar RH: Decreased natural cytotoxicity in mice with high incidence of mammary adenocarcinoma. Clin Immunol Immunopathol. 1986, 38: 265-273. 10.1016/0090-1229(86)90144-3.View ArticlePubMedGoogle Scholar
  13. Cook JL, Lewis AM: Immunological surveillance against DNA-virus-transformed cells: correlations between natural killer cell cytolytic competence and tumor susceptibility of athymic rodents. J Virol. 1987, 61: 2155-2161.PubMed CentralPubMedGoogle Scholar
  14. Shanker A, Buferne M, Schmitt-Verhulst AM: Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology. 2010, 129: 41-54. 10.1111/j.1365-2567.2009.03150.x.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Goncalves A, Andre P, Romagne F, Thibault G: Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011, 121: 3609-3622. 10.1172/JCI45816.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M: Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 2011, 17: 700-707. 10.1038/nm.2366.View ArticlePubMedGoogle Scholar
  17. Costello RT, Knoblauch B, Sanchez C, Mercier D, Le Treut T, Sebahoun G: Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia. Immunology. 2012, 135: 151-157. 10.1111/j.1365-2567.2011.03521.x.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Ascierto ML, Kmieciak M, Idowu M, Grimes M, Dumur C, Wang E, Marincola FM, Bear HD, Manjili MH: Signatures of Immune Function Genes Associated with Recurrence-Free Survival in Breast Cancer Patients. J Immunother. 2010, 33: 881-881.Google Scholar
  19. Marras F, Bozzano F, De Maria A: Involvement of activating NK cell receptors and their modulation in pathogen immunity. J Biomed Biotechnol. 2011, 2011: 152430-PubMed CentralView ArticlePubMedGoogle Scholar
  20. Moretta A, Biassoni R, Bottino C, Moretta L: Surface receptors delivering opposite signals regulate the function of human NK cells. Semin Immunol. 2000, 12: 129-138. 10.1006/smim.2000.0215.View ArticlePubMedGoogle Scholar
  21. Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M, Monaco A, Liu H: Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics. 2009, 10: 301-10.1186/1471-2164-10-301.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM: High-fidelity mRNA amplification for gene profiling. Nat Biotechnol. 2000, 18: 457-459. 10.1038/74546.View ArticlePubMedGoogle Scholar
  23. Wang E: RNA amplification for successful gene profiling analysis. J Transl Med. 2005, 3: 28-10.1186/1479-5876-3-28.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
  25. Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurro V, Smith K, Hu N, Su H, Taylor PR: Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics. 2004, 5: 55-10.1186/1471-2164-5-55.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y: Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 2007, 3: 11-17.PubMed CentralPubMedGoogle Scholar
  27. Bair E, Tibshirani R: Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol. 2004, 2: E108-10.1371/journal.pbio.0020108.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J: GOBO: gene expression-based outcome for breast cancer online. PLoS One. 2011, 6: e17911-10.1371/journal.pone.0017911.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 2005, 102: 13550-13555. 10.1073/pnas.0506230102.PubMed CentralView ArticlePubMedGoogle Scholar
  30. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005, 7: R953-964. 10.1186/bcr1325.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA. 2010, 107: 10208-10213. 10.1073/pnas.0907011107.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d’Assignies MS: Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007, 13: 3207-3214. 10.1158/1078-0432.CCR-06-2765.View ArticlePubMedGoogle Scholar
  33. Binsky-Ehrenreich I, Marom A, Sobotta MC, Shvidel L, Berrebi A, Hazan-Halevy I, Kay S, Aloshin A, Sagi I, Goldenberg DM: CD84 is a survival receptor for CLL cells. Oncogene. 2013,  :  -[Epub ahead of print]Google Scholar
  34. Shevach EM: Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009, 30: 636-645. 10.1016/j.immuni.2009.04.010.View ArticlePubMedGoogle Scholar
  35. Mantovani A, Romero P, Palucka AK, Marincola FM: Tumour immunity: effector response to tumour and role of the microenvironment. Lancet. 2008, 371: 771-783. 10.1016/S0140-6736(08)60241-X.View ArticlePubMedGoogle Scholar
  36. Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, Engle AM, Thomas JM, Wang E, Marincola FM, Bedognetti D: Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med. 2011, 9: 174-10.1186/1479-5876-9-174.PubMed CentralView ArticlePubMedGoogle Scholar
  37. Shanker A, Marincola FM: Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother. 2011, 60: 1061-1074. 10.1007/s00262-011-1053-z.PubMed CentralView ArticlePubMedGoogle Scholar
  38. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M: The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997, 79: 2320-2328. 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
  39. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T: Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000, 88: 577-583. 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V.View ArticlePubMedGoogle Scholar
  40. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, Zuil M, Callol L: Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002, 35: 23-28. 10.1016/S0169-5002(01)00292-6.View ArticlePubMedGoogle Scholar
  41. Donskov F, von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006, 24: 1997-2005. 10.1200/JCO.2005.03.9594.View ArticlePubMedGoogle Scholar
  42. Jochems C, Schlom J: Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood). 2011, 236: 567-579. 10.1258/ebm.2011.011007.View ArticleGoogle Scholar
  43. Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, Charaffe-Jaufret E, Birnbaum D, Moretta A, Olive D: Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition. Cancer Res. 2011, 71: 6621-6632. 10.1158/0008-5472.CAN-11-0792.View ArticlePubMedGoogle Scholar
  44. Malhotra A, Shanker A: NK cells: immune cross-talk and therapeutic implications. Immunotherapy. 2011, 3: 1143-1166. 10.2217/imt.11.102.PubMed CentralView ArticlePubMedGoogle Scholar
  45. Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M: Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol. 2004, 172: 3994-3998.View ArticlePubMedGoogle Scholar
  46. Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, Smyth MJ: DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol. 2010, 184: 902-911. 10.4049/jimmunol.0903225.View ArticlePubMedGoogle Scholar
  47. Mace EM, Zhang J, Siminovitch KA, Takei F: Elucidation of the integrin LFA-1-mediated signaling pathway of actin polarization in natural killer cells. Blood. 2010, 116: 1272-1279. 10.1182/blood-2009-12-261487.View ArticlePubMedGoogle Scholar
  48. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, Andrews DM, Smyth MJ, Colonna M: DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med. 2008, 205: 2965-2973. 10.1084/jem.20081752.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A: Surface NK receptors and their ligands on tumor cells. Semin Immunol. 2006, 18: 151-158. 10.1016/j.smim.2006.03.002.View ArticlePubMedGoogle Scholar
  50. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L: Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001, 19: 197-223. 10.1146/annurev.immunol.19.1.197.View ArticlePubMedGoogle Scholar
  51. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, Tagliabue E, Balsari A: FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009, 27: 1746-1752. 10.1200/JCO.2008.17.9036.View ArticlePubMedGoogle Scholar
  52. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, Tsang KY, Licchetta A, Mannucci S, Loiacono L: Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother. 2010, 33: 435-441. 10.1097/CJI.0b013e3181d32f01.View ArticlePubMedGoogle Scholar
  53. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F, Galon J: Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011, 71: 1263-1271. 10.1158/0008-5472.CAN-10-2907.View ArticlePubMedGoogle Scholar
  54. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B: gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011, 364: 2119-2127. 10.1056/NEJMoa1012863.PubMed CentralView ArticlePubMedGoogle Scholar
  55. Le DT, Ladle BH, Lee T, Weiss V, Yao X, Leubner A, Armstrong TD, Jaffee EM: CD8 Foxp3 tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. Int J Cancer. 2011, 129: 636-647. 10.1002/ijc.25693.PubMed CentralView ArticlePubMedGoogle Scholar
  56. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T, Barda AK, Gourgoulianis KI, Germenis AE: Foxp3 expression in human cancer cells. J Transl Med. 2008, 6: 19-10.1186/1479-5876-6-19.PubMed CentralView ArticlePubMedGoogle Scholar
  57. Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P, Zuo T: Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009, 16: 336-346. 10.1016/j.ccr.2009.08.016.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Ascierto et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

Journal of Translational Medicine

ISSN: 1479-5876

Contact us